Focus shifts to short-stay residents to prevent future COVID-19 outbreaks … U.S. COVID vaccination rates to plateau in April, survey results suggest … U.S. hits COVID shot target; 25% of adults now...
Clinical briefs for Thursday, June 3
By
Alicia Lasek
Jun 03, 2021
Nursing homes’ smaller but continued COVID outbreaks blamed on unvaccinated staff, report finds … U.S. to test mixed COVID vaccine booster dose schedules in vaccinated adults … WHO plans to simplify...
Robust response to virus variants expected in former COVID patients and the vaccinated
By
Alicia Lasek
Mar 31, 2021
Blood samples from recovered COVID-19 patients show that they and their vaccinated peers should be able to fend off the virus and its variants in future encounters, NIH researchers say.
Clinical briefs for Thursday, Sept. 16
By
Alicia Lasek
Sep 16, 2021
U.S. to limit states’ access to COVID antibody treatments as demand rises … Aggressively reducing Alzheimer’s risk factors could mean 1.2 million fewer cases in 2050: experts … NIH launches nationwide...
SNF-linked wound clinics saw fewer patients during pandemic but unchanged outcomes
By
Alicia Lasek
Nov 10, 2021
Investigators expected that wound outcomes would be adversely affected by pandemic disruptions. But data from hundreds of wound care clinics in the United States show otherwise.
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
Nursing home study reveals ‘dramatic’ fluctuations in prescribing of COVID-19 meds
By
Alicia Lasek
May 26, 2023
Investigators tracked the use of COVID-19 medications in 11 U.S. nursing home chains, describing prescribing patterns that shed new light on the challenges of pandemic clinical care.
25 percent of COVID patients have post-acute symptoms; Report highlights emerging care needs
By
Alicia Lasek
Jun 18, 2021
A analysis based on nearly two million private U.S. healthcare claims has identified the most common post-COVID conditions with a focus on age, gender, mental health conditions and mortality. Even 19%...
Feds identify promising and ‘urgently needed’ COVID antiviral drug
By
Alicia Lasek
Jun 04, 2021
The experimental drug TEMPOL has shown promise in early studies, halting the activity of a viral enzyme and limiting the severity of SARS-CoV-2 infections.
An antibody cocktail that halts disease progression in sick COVD-19 patients has been shown to prevent the disease altogether in healthy people who live in close contact with an infected person, the drugmaker...